| Jul 29 |
Celldex phase 2 barzolvolimab trial in urticaria meets key endpoint, but stock slips
|
| Jul 29 |
Celldex Therapeutics Presents Positive Topline Results from Barzolvolimab Phase 2 Study in Chronic Inducible Urticaria
|
| Jul 28 |
ViaSat & AST SpaceMobile Are Among Top 6 Mid Cap Stocks That Shined The Brightest Last Week (July 21-July 27): Are The Others In Your Portfolio?
|
| Jul 28 |
Companies Like Celldex Therapeutics (NASDAQ:CLDX) Can Afford To Invest In Growth
|
| Jul 17 |
Caribou lays off staff; Roche walks away from Relay
|
| Jul 16 |
Analyst Expectations For Celldex Therapeutics's Future
|
| Jul 16 |
Celldex Therapeutics Initiates Global Phase 3 Program for Barzolvolimab in Patients with Chronic Spontaneous Urticaria
|
| Jun 18 |
Stifel starts Celldex at buy, sees lead drug as potential blockbuster
|
| Jun 11 |
Insider Sale: SVP, Chief Medical Officer Diane Young Sells 45,000 Shares of Celldex ...
|
| Jun 11 |
Celldex initiated to outperform at Wolfe on barzolvolimab for skin disease
|
